Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) Drops in Trading Today – Down by 5.63%

0
67

The company is so far trading down by 5.63% since yesterday’s close of 2.31 giving up $0.13 . More than 79,804 shares have been traded.

It is currently trading at $2.18 which is marginally over the 50 day moving average of $2.18 and much higher than the 200 day moving average of $1.90. The 50 day moving average was up $0.00 or +0.09% whereas the 200 day moving average was up $0.28 or +14.53%.

Traders are a little more bullish on the company recently if you put credence in the change in short interest. The firm saw a fall in short interest of -11.90% between September 15, 2017 and September 29, 2017. Short shares fell from 365,911 to 322,369 over that period. The short-interest ratio decreased to 2.0 and the percentage of shorted shares is 0.04% as of September 29.

Here are a few substantial investment firms who have updated their positions. Menta Capital LLC trimmed its position by selling 2,800 shares a decrease of 3.7% as of 06/30/2017. Menta Capital LLC claims 72,419 shares worth $111,000. The value of the position overall is down by 23.4%. Kcg Holdings, Inc. divested its ownership by shedding 7,373 shares a decrease of 34.6%. Kcg Holdings, Inc. now holds 13,942 shares with a value of $21,000. The total value of its holdings decreased 48.8%.

Psagot Investment House Ltd. added to its stake by buying 34,489 shares an increase of 12,679.8% in the quarter. Psagot Investment House Ltd. controls 34,761 shares valued at $53,000. The total value of its holdings increased 5,200.0%. As of the end of the quarter Ubs Group Ag had sold 3,546 shares trimming its holdings by 46.9%. The value of the total investment in Kitov Pharmaceuticals Holdings went from $15,000 to $6,000 decreasing 60.0% for the reporting period.

Kitov Pharmaceuticals Holdings Ltd., through its subsidiary, Kitov Pharmaceuticals Ltd., operates as a clinical development stage biopharmaceutical company. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company’s lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing KIT-301, which is based on the generic drugs naproxen and isradipine. . The company was formerly known as Mainrom Line Logistics Ltd. and changed its name to Kitov Pharmaceuticals Holdings Ltd. in August 2013. Kitov Pharmaceuticals Holdings Ltd. was incorporated in 1968 is based in Tel Aviv, Israel..